DANVERS, Mass., July 12 /PRNewswire-FirstCall/ -- Medwave, Inc. , the innovator in sensor-based, non-invasive blood pressure measuring solutions, announced today that it has been granted two new U.S. patents and three new foreign patents over the past nine months, bringing the U.S. patent total to 27 granted patents and the foreign patent total to 11 granted patents. Medwave also has seven additional U.S. patents pending and four additional foreign patents pending, one of which recently received a notification to grant. Over the years, Medwave has aggressively sought to protect the intellectual property associated with its sensor-based blood pressure monitoring technology.
In addition to protecting its inventions, Medwave has dedicated a great deal of time, effort, and resources on proving their efficacy. There have been numerous studies published and/or presented that indicate that the comfort, convenience, and accuracy of Medwave's sensor-based solutions provide a better alternative across a multitude of clinical settings and on patients whose blood pressure measurements are traditionally very difficult to monitor. In February of this year, Medwave's Primo(TM) spot-check blood pressure monitoring device received FDA clearance, and just recently, Medwave announced the submission of its Fusion(TM) Non-Invasive Patient Monitor System with Vital Signs Options to the FDA for 510(k) review. Both products embody Medwave's patented, core sensor-based blood pressure monitoring technology.
Tim O'Malley, President and CEO of Medwave, Inc., stated, "Over the past few years, Medwave has been focused on positioning its technology as a logical replacement to non-invasive blood pressure cuff products, technology that has not seen significant change in over a century. The blood pressure monitoring market has an enormous scope, and blood pressure is one vital sign that is required in all clinical settings. There is no other area in medicine where technology as old as the cuff is still being used as a basis for so many critical decisions in such a multitude of locations. We believe Medwave's sensor-based, non-invasive blood pressure measurement technology is not only the sensible alternative to the antiquated cuff technology, but the quintessential modern solution, therefore we have been deliberate and strategic in our approach to our intellectual property position. We are pleased to have received these recent patent awards and are looking forward to future activity in this aspect of our business."
About Medwave
Medwave, Inc. develops, manufactures, and distributes sensor-based non-invasive blood pressure solutions. Medwave's suite of products is designed for use in hospitals, clinics, doctor's offices and almost anywhere else blood pressure monitoring takes place. Medwave has the required technology clearances to market its technology in the United States, Europe, and Asia. Medwave's technology is installed in over 500 hospitals and clinics worldwide. Medwave trades on the NASDAQ small cap market under the symbol MDWV. For more information, visit http://www.medwave.com .
Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time are considered "forward-looking statements" and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in Medwave's filings with the SEC, have affected and, in the future, could affect Medwave's actual results: resistance to the acceptance of new medical products, the market acceptance of the Primo(TM) system, the Vasotrac(R) system and other products of Medwave, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of Medwave's products, Medwave's success in creating effective distribution channels for its products, Medwave's ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), Legato(TM), Primo(TM), and Fusion(TM) are trademarks of Medwave, Inc.
Medwave, Inc.CONTACT: Investor Relations, Jodie Chastain, +1-800-894-7601, or MediaRelations, Kevin Sawyer, +1-612-465-8356, both of Medwave, Inc.
Web site: http://www.medwave.com/
